Clinical Study CAN-003
This clinical study is designed to help oncologists and health authorities understand how effective the vaccine therapy might be in patients with ovarian cancer that is in remission. In some patients, even though the ovarian cancer is in remission after surgery and chemotherapy, there is still a possibility that some ovarian cancer cells have been left behind. These cells may multiply causing the tumour to reappear. CVac™ has been designed to try to prevent recurrence of the tumour. The CVac™ vaccine is prepared individually for each patient, and it is given 10 times over a year. This study looks at how long it takes for any cancer cells that may still be in the body to start growing again. The study lasts approximately two years for each patient.
The study has recently completed recruiting patients.
|
|